{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:48:41Z","timestamp":1791388121272,"version":"4.3.3"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"The Wellcome Trust","doi-asserted-by":"crossref","award":["092805"],"award-info":[{"award-number":["092805"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"The Wellcome Trust","doi-asserted-by":"crossref","award":["202789"],"award-info":[{"award-number":["202789"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"name":"University of Glasgow PhD Scholarship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The involvement of the complement pathway in Guillain\u2013Barr\u00e9 syndrome pathogenesis has been demonstrated in both patient biosamples and animal models. One proposed mechanism is that anti-ganglioside antibodies mediate neural membrane injury through the activation of complement and the formation of membrane attack complex pores, thereby allowing the uncontrolled influx of ions, including calcium, intracellularly. Calcium influx activates the calcium-dependent protease calpain, leading to the cleavage of neural cytoskeletal and transmembrane proteins and contributing to subsequent functional failure. Complement inhibition has been demonstrated to provide effective protection from injury in anti-ganglioside antibody-mediated mouse models of axonal variants of Guillain\u2013Barr\u00e9 syndrome; however, the role of complement in the pathogenesis of demyelinating variants has yet to be established. Thus, it is currently unknown whether complement inhibition would be an effective therapeutic for Guillain\u2013Barr\u00e9 syndrome patients with injuries to the Schwann cell membrane. To address this, we recently developed a mouse model whereby the Schwann cell membrane was selectively targeted with an anti-GM1 antibody resulting in significant disruption to the axo-glial junction and cytoplasmic paranodal loops, presenting as conduction block. Herein, we utilize this Schwann cell nodal membrane injury model to determine the relevance of inhibiting complement activation. We addressed the early complement component C2 as the therapeutic target within the complement cascade by using the anti-C2 humanized monoclonal antibody, ARGX-117. This anti-C2 antibody blocks the formation of C3 convertase, specifically inhibiting the classical and lectin complement pathways and preventing the production of downstream harmful anaphylatoxins (C3a and C5a) and membrane attack complexes. Here, we demonstrate that C2 inhibition significantly attenuates injury to paranodal proteins at the node of Ranvier and improves respiratory function in ex vivo and in vivo Schwann cell nodal membrane injury models. In parallel studies, C2 inhibition also protects axonal integrity in our well-established model of acute motor axonal neuropathy mediated by both mouse and human anti-GM1 antibodies. These data demonstrate that complement inhibition prevents injury in a Schwann cell nodal membrane injury model, which is representative of neuropathies associated with anti-GM1 antibodies, including Guillain\u2013Barr\u00e9 syndrome and multifocal motor neuropathy. This outcome suggests that both the motor axonal and demyelinating variants of Guillain\u2013Barr\u00e9 syndrome should be included in future complement inhibition clinical trials.<\/jats:p>","DOI":"10.1093\/braincomms\/fcac306","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T21:39:28Z","timestamp":1669066768000},"source":"Crossref","is-referenced-by-count":21,"title":["Complement inhibition prevents glial nodal membrane injury in a GM1 antibody-mediated mouse model"],"prefix":"10.1093","volume":"4","author":[{"given":"Clare I","family":"Campbell","sequence":"first","affiliation":[{"name":"Institute of Infection, Immunity and Inflammation, University of Glasgow , Glasgow G12 8TA , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhona","family":"McGonigal","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunity and Inflammation, University of Glasgow , Glasgow G12 8TA , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A","family":"Barrie","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunity and Inflammation, University of Glasgow , Glasgow G12 8TA , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien","family":"Delaere","sequence":"additional","affiliation":[{"name":"argenx BV , Zwijnaarde, 9052 Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bracke","sequence":"additional","affiliation":[{"name":"argenx BV , Zwijnaarde, 9052 Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine E","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunity and Inflammation, University of Glasgow , Glasgow G12 8TA , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denggao","family":"Yao","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunity and Inflammation, University of Glasgow , Glasgow G12 8TA , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Delahaye","sequence":"additional","affiliation":[{"name":"argenx BV , Zwijnaarde, 9052 Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7631-399X","authenticated-orcid":false,"given":"Inge","family":"Van de Walle","sequence":"additional","affiliation":[{"name":"argenx BV , Zwijnaarde, 9052 Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5997-1683","authenticated-orcid":false,"given":"Hugh J","family":"Willison","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunity and Inflammation, University of Glasgow , Glasgow G12 8TA , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"issue":"5","key":"2022121316310801200_fcac306-B1","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.410440512","article-title":"Electrophysiological classification of Guillain-Barr\u00e9 syndrome: Clinical associations and outcome","volume":"44","author":"Hadden","year":"1998","journal-title":"Ann Neurol"},{"issue":"1","key":"2022121316310801200_fcac306-B2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00005792-194902010-00003","article-title":"The Landry-Guillain-Barr\u00e9 syndrome: A clinicopathologic report of fifty fatal cases and a critique of the literature","volume":"28","author":"Haymaker","year":"1949","journal-title":"Medicine (Baltimore)."},{"issue":"3","key":"2022121316310801200_fcac306-B3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00005792-196905000-00001","article-title":"The inflammatory lesion in idiopathic polyneuritis","volume":"48","author":"Asbury","year":"1969","journal-title":"Medicine (Baltimore)."},{"issue":"5","key":"2022121316310801200_fcac306-B4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/ana.410390512","article-title":"Immune attack on the schwann cell surface in acute inflammatory demyelinating polyneuropathy","volume":"39","author":"Hafer-Macko","year":"1996","journal-title":"Ann Neurol"},{"issue":"12","key":"2022121316310801200_fcac306-B5","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1212\/WNL.40.12.1900","article-title":"Acute axonal polyneuropathy associated with anti-GM1 antibodies following campylobacter enteritis","volume":"40","author":"Yuki","year":"1990","journal-title":"Neurology"},{"issue":"1","key":"2022121316310801200_fcac306-B6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ana.410240113","article-title":"A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside","volume":"24","author":"Pestronk","year":"1988","journal-title":"Ann Neurol"},{"issue":"5","key":"2022121316310801200_fcac306-B7","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/ana.410380516","article-title":"Anti-ganglioside GM1 antibodies in Guillain-Barr\u00e9 syndrome and their relationship to campylobacter jejuni infection","volume":"38","author":"Rees","year":"1995","journal-title":"Ann Neurol"},{"issue":"9","key":"2022121316310801200_fcac306-B8","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/brain\/awh231","article-title":"Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy","volume":"127","author":"Halstead","year":"2004","journal-title":"Brain"},{"issue":"10","key":"2022121316310801200_fcac306-B9","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1073\/pnas.69.10.2954","article-title":"Mechanism of cytolysis by complement","volume":"69","author":"Mayer","year":"1972","journal-title":"Proc Natl Acad Sci"},{"key":"2022121316310801200_fcac306-B10","doi-asserted-by":"crossref","first-page":"114127","DOI":"10.1016\/j.expneurol.2022.114127","article-title":"Real time imaging of intra-axonal calcium flux in an explant mouse model of axonal Guillain-Barr\u00e9 syndrome","volume":"355","author":"Cunningham","year":"2022","journal-title":"Exp Neurol."},{"issue":"7","key":"2022121316310801200_fcac306-B11","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/brain\/awq119","article-title":"Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice","volume":"133","author":"McGonigal","year":"2010","journal-title":"Brain"},{"issue":"11","key":"2022121316310801200_fcac306-B12","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1093\/brain\/awg254","article-title":"Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury","volume":"126","author":"O\u2019Hanlon","year":"2003","journal-title":"Brain"},{"issue":"12","key":"2022121316310801200_fcac306-B13","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/0020-711X(90)90240-4","article-title":"In vitro digestion of spectrin, protein 4.1 and ankyrin by erythrocyte calcium dependent neutral protease (calpain I)","volume":"22","author":"Boivin","year":"1990","journal-title":"Int J Biochem"},{"issue":"4","key":"2022121316310801200_fcac306-B14","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1471-4159.1983.tb08072.x","article-title":"Identification of Ca2+-activated neutral protease in the peripheral nerve and its effects on neurofilament degeneration","volume":"40","author":"Kamakura","year":"1983","journal-title":"J Neurochem"},{"issue":"5","key":"2022121316310801200_fcac306-B15","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awm316","article-title":"Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model","volume":"131","author":"Halstead","year":"2008","journal-title":"Brain"},{"issue":"1","key":"2022121316310801200_fcac306-B16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jns.12194","article-title":"Inhibition of complement in Guillain-Barr\u00e9 syndrome: The ICA-GBS study","volume":"22","author":"Davidson","year":"2017","journal-title":"J Peripheral Nervous Syst"},{"key":"2022121316310801200_fcac306-B17","author":"Islam","year":"2020"},{"issue":"6","key":"2022121316310801200_fcac306-B18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1474-4422(18)30114-5","article-title":"Safety and efficacy of eculizumab in Guillain-Barr\u00e9 syndrome: A multicentre, double-blind, randomised phase 2 trial","volume":"17","author":"Misawa","year":"2018","journal-title":"Lancet Neurol"},{"issue":"1","key":"2022121316310801200_fcac306-B19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40478-016-0291-x","article-title":"C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy","volume":"4","author":"McGonigal","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"2022121316310801200_fcac306-B20","author":"McGonigal","year":"2022"},{"issue":"3","key":"2022121316310801200_fcac306-B21","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1523\/JNEUROSCI.3996-13.2014","article-title":"Neuronal expression of GalNAc transferase is sufficient to prevent the age-related neurodegenerative phenotype of complex ganglioside-deficient mice","volume":"34","author":"Yao","year":"2014","journal-title":"J Neurosci"},{"issue":"1","key":"2022121316310801200_fcac306-B22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jneuroim.2005.04.011","article-title":"Characterisation of the immunoglobulin variable region gene usage encoding the murine anti-ganglioside antibody repertoire","volume":"165","author":"Boffey","year":"2005","journal-title":"J Neuroimmunol"},{"issue":"3","key":"2022121316310801200_fcac306-B23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/glycob\/cwl074","article-title":"Solid phase immunoadsorption for therapeutic and analytical studies on neuropathy-associated anti-GM1 antibodies","volume":"17","author":"Townson","year":"2007","journal-title":"Glycobiol"},{"issue":"4","key":"2022121316310801200_fcac306-B24","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ana.410350416","article-title":"Cloning of human anti-GM1 antibodies from motor neuropathy patients","volume":"35","author":"Willison","year":"1994","journal-title":"Ann Neurol"},{"key":"2022121316310801200_fcac306-B25","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jaci.2020.08.028","article-title":"ARGX-117, a therapeutic complement inhibiting antibody targeting C2","volume":"147","author":"Van de Walle","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2022121316310801200_fcac306-B26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1172\/JCI37338","article-title":"The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice","volume":"119","author":"Greenshields","year":"2009","journal-title":"J Clin Invest"},{"issue":"12","key":"2022121316310801200_fcac306-B27","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1038\/nn.3858","article-title":"Glial ankyrins facilitate paranodal axoglial junction assembly","volume":"17","author":"Chang","year":"2014","journal-title":"Nat Neurosci"},{"issue":"3","key":"2022121316310801200_fcac306-B28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0960-9822(01)00680-7","article-title":"Neurofascin is a glial receptor for the paranodin\/caspr-contactin axonal complex at the axoglial junction","volume":"12","author":"Charles","year":"2002","journal-title":"Curr Biol"},{"issue":"5","key":"2022121316310801200_fcac306-B29","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/ana.410230503","article-title":"Serum antibodies to gangliosides in Guillain-Barre syndrome","volume":"23","author":"Ilyas","year":"1988","journal-title":"Ann Neurol"},{"issue":"4","key":"2022121316310801200_fcac306-B30","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ana.410400414","article-title":"Acute motor axonal neuropathy: An antibody-mediated attack on axolemma","volume":"40","author":"Hafer-Macko","year":"1996","journal-title":"Ann Neurol"},{"issue":"1\u20132","key":"2022121316310801200_fcac306-B31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jneuroim.2008.09.016","article-title":"Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain\u2013Barr\u00e9 syndrome","volume":"205","author":"Phongsisay","year":"2008","journal-title":"J Neuroimmunol"},{"issue":"1","key":"2022121316310801200_fcac306-B32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4049\/jimmunol.120.1.109","article-title":"Chemotactic response to human C3a and C5a anaphylatoxins: I. Evaluation of C3a. And C5a leukotaxis in vitro and under simulated in vivo conditions","volume":"120","author":"Fernandez","year":"1978","journal-title":"J Immunol"},{"issue":"9","key":"2022121316310801200_fcac306-B33","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41573-019-0031-6","article-title":"Clinical promise of next-generation complement therapeutics","volume":"18","author":"Mastellos","year":"2019","journal-title":"Nat Rev Drug Dis"},{"issue":"6","key":"2022121316310801200_fcac306-B34","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.4049\/jimmunol.155.6.3049","article-title":"Analysis of anti-GM1 ganglioside IgM antibodies cloned from motor neuropathy patients demonstrates diverse V region gene usage with extensive somatic mutation","volume":"155","author":"Paterson","year":"1995","journal-title":"The J Immunol"},{"issue":"2","key":"2022121316310801200_fcac306-B35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neuron.2005.06.026","article-title":"Gliomedin mediates schwann cell-axon interaction and the molecular assembly of the nodes of Ranvier","volume":"47","author":"Eshed","year":"2005","journal-title":"Neuron"},{"issue":"6","key":"2022121316310801200_fcac306-B36","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1172\/JCI6837","article-title":"Monoclonal antibodies raised against Guillain-Barr\u00e9 syndrome\u2013associated campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations","volume":"104","author":"Goodyear","year":"1999","journal-title":"J Clin Invest"},{"key":"2022121316310801200_fcac306-B37","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jneuroim.2008.05.028","article-title":"The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain\u2013Barr\u00e9 syndrome","volume":"201","author":"Willison","year":"2008","journal-title":"J Neuroimmunol"},{"issue":"10","key":"2022121316310801200_fcac306-B38","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1212\/WNL.0000000000000205","article-title":"Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg","volume":"82","author":"Querol","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"2022121316310801200_fcac306-B39","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ana.23794","article-title":"Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy","volume":"73","author":"Querol","year":"2013","journal-title":"Ann Neurol"},{"issue":"4","key":"2022121316310801200_fcac306-B40","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/brain\/awx012","article-title":"Co-cultures with stem cell-derived human sensory neurons reveal regulators of peripheral myelination","volume":"140","author":"Clark","year":"2017","journal-title":"Brain"},{"issue":"2","key":"2022121316310801200_fcac306-B41","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1529-8027.2011.00328.x","article-title":"An open label clinical trial of complement inhibition in multifocal motor neuropathy","volume":"16","author":"Fitzpatrick","year":"2011","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"2022121316310801200_fcac306-B42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s10875-012-9779-8","article-title":"Immune pathogenesis and treatment of multifocal motor neuropathy","volume":"33","author":"Vlam","year":"2013","journal-title":"J Clin Immunol"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcac306\/47206989\/fcac306.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/4\/6\/fcac306\/47834995\/fcac306.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/4\/6\/fcac306\/47834995\/fcac306.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T09:18:18Z","timestamp":1678699098000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcac306\/6841348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcac306","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,11,2]]},"article-number":"fcac306"}}